Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics Inc. reports developments as a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company’s lead candidate, ONP-002, is an investigational intranasal neurosteroid being evaluated for concussion and mild traumatic brain injury, with updates centered on clinical trial operations, regulatory clearances, site activity and dosing milestones.
Company news also covers annual-report disclosures, operating and financial results, capital-structure actions, material agreements, shareholder voting matters and governance updates. Oragenics’ communications frequently connect its CNS strategy, intranasal delivery platform and public-company reporting obligations as an NYSE American-listed biotechnology issuer.
Oragenics (NYSE American: OGEN) engaged DUCK FLATS Pharma as its U.S. IND readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design for its intranasal concussion therapy ONP-002.
The engagement aims to align an upcoming Phase 2a trial in Australia with U.S. regulatory strategy, leverage DUCK FLATS’ ~38 years of experience and prior roles on ~40 drug programs and >60 FDA-approved NDAs, and help advance ONP-002 toward a U.S. Phase 2b trial and later-stage development. The release cites a projected global concussion market >$9B by 2027 and a nasal drug delivery market >$125B by 2030.
Oragenics (NYSE American: OGEN) will participate in the SCOPE Summit 2026, Feb 2–5 in Orlando, engaging clinical operations leaders ahead of its planned Phase 2a trial of an intranasal concussion therapeutic in Australia.
The company highlighted its lead candidate ONP-002 and its intranasal delivery platform aimed at targeted, non‑invasive brain delivery for concussion and mild TBI.
Oragenics (NYSE American: OGEN) will present at the Sequire Investor Summit 2026 in San Juan, Puerto Rico, January 20-22, 2026.
The presentation will cover Oragenics' ONP-002 clinical program targeting concussion and mild traumatic brain injury and the company’s plan to advance ONP-002 into Phase 2a studies. The event is hosted at the Condado Vanderbilt Hotel; investors should review the summit agenda for the exact date and time of Oragenics’ session. For registration and conference details, visit the official event website.
Oragenics (NYSE American: OGEN) reported Q3 2025 operational, strategic, and financial milestones as it prepares for Phase IIa clinical work in Australia with anticipated initiation in Q4 2025–Q1 2026. Key achievements include regaining NYSE American compliance on Oct 20, 2025, completing a $16.5M gross capital raise (net proceeds ~$15.2M), eliminating a $3M note payable, securing HREC approval earlier in 2025 with amendments under review, appointing Southern Star Research as CRO, and contracting Sterling Pharma Solutions for cGMP manufacturing. The company also announced a strategic AI collaboration with Receptor.AI to accelerate its molecule pipeline beyond ONP-002 and reported year-to-date R&D expense reduction of 30%.
Oragenics (NYSE American: OGEN) regained full NYSE American compliance effective October 20, 2025 after restoring stockholders' equity above the required $6 million threshold.
The company closed a $16.5 million public offering of Series H convertible preferred stock on July 2, 2025, which restored equity and provides runway to advance lead candidate ONP-002 through Phase IIa in Australia and to prepare for potential U.S. Phase IIb trials.
Oragenics (NASDAQ: OGEN) announced a strategic collaboration with Receptor.AI to apply AI-driven receptor profiling to Oragenics' molecules acquired in 2023, aiming to accelerate preclinical candidate identification for neurological and psychiatric indications. The work intends to guide laboratory validation and prioritize targets across Alzheimer’s, Parkinson’s, PTSD, opioid addiction, and anxiety. Oragenics remains focused on advancing its lead candidate, ONP-002, with a Phase IIa concussion trial initiation expected in Q4 2025. The company frames the partnership as a step from a single-asset model toward a diversified intranasal neurology platform while emphasizing capital-efficient discovery.
Oragenics (NYSE American: OGEN) provided a Q2 2025 shareholder update highlighting progress in developing ONP-002, its lead candidate for concussion treatment. The company secured a $16.5 million capital raise through Series H Convertible Preferred Stock and Warrants, with net proceeds of $15.2 million.
Key operational achievements include HREC approval in Australia, appointment of Southern Star Research as CRO, and a cGMP manufacturing agreement with Sterling Pharma Solutions. The company demonstrated financial discipline with a 50% reduction in R&D expenses and 8% decrease in administrative costs.
Oragenics plans to initiate Phase IIa trials in Q3 2025, followed by IND submission to FDA for Phase IIb trials in Q3-Q4 2025. The company targets the $8.9 billion global concussion market by 2027, aiming to become the first FDA-approved pharmacological treatment for concussion.
Oragenics (NYSE American: OGEN) has selected Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, a drug candidate for concussion treatment. The trial will be a randomized, double-blind, placebo-controlled study evaluating ONP-002 in adults with mild traumatic brain injury (mTBI).
The company has already secured Human Research Ethics Committee (HREC) approval and chosen Australia for the trial due to its streamlined regulatory process, experienced trial sites, and R&D tax incentive benefits. ONP-002 is a proprietary intranasal neurosteroid that has shown promising results in preclinical models, including reduced brain inflammation and improved cognitive function.
Oragenics (NYSE American: OGEN) has secured a manufacturing agreement with Sterling Pharma Solutions for the GMP production of ONP-002, its lead drug candidate for concussion treatment. The U.S.-based manufacturing partnership will support Oragenics' planned Phase IIb clinical trials expected to begin in 2026.
The collaboration with Sterling's facility in Cary, North Carolina, represents a crucial milestone in Oragenics' development strategy, ensuring domestic production capabilities for their upcoming clinical and regulatory efforts. The trials will evaluate ONP-002's early efficacy in patients with mild traumatic brain injury (mTBI), addressing a condition that currently lacks FDA-approved pharmacological treatments.
Oragenics (NYSE American: OGEN) has successfully closed a public offering, raising $16.5 million through the issuance of 660,000 shares of Series H Convertible Preferred Stock and Warrants. Each unit, comprising one preferred share and one warrant, was priced at $25.00. The warrants could potentially generate an additional $16.5 million if fully exercised.
The preferred stock is convertible at $2.50 per common share, and the warrants expire in five years. The proceeds will primarily fund the development of ONP-002, an intranasal drug candidate for treating concussion, along with repaying a $3 million bridge note and supporting general corporate purposes.